Search Results
Jul 23, 2026, 13:00 ET Tessera Therapeutics Appoints Joseph Romanelli as President and Chief Executive Officer
the future as he embarks on a new role leading a commercial stage biotech company."Romanelli joins Tessera from Merck & Co., Inc. (NYSE: MRK) where he most recently served as President, Human Health International, and a member of the company's Executive Team. In that role, he was responsible
More news about: Tessera Therapeutics
Jul 01, 2026, 06:31 ET 샨타 바이오로직스, 카트리지 충전 마감 협력 발표
MRK 라주(MRK Raju) 박사+91 996 358 1033
More news about: Shantha Biologics
Jun 30, 2026, 23:45 ET Shantha Biologics gibt Zusammenarbeit im Bereich der Abfüllung und Endverarbeitung von Karpulen bekannt
Dr. MRK Raju+91 996 358 1033
More news about: Shantha Biologics
Jun 30, 2026, 16:21 ET Shantha Biologics anuncia una colaboración para el llenado y acabado de cartuchos
Dr MRK Raju +91 996 358 1033
More news about: Shantha Biologics
Jun 30, 2026, 16:16 ET Shantha Biologics annonce un partenariat dans le domaine du remplissage et de la finition de cartouches
MRK Raju+91 996 358 1033
More news about: Shantha Biologics
Jun 30, 2026, 09:13 ET Shantha Biologics Announces Cartridge Fill-Finish Collaboration
Dr MRK Raju+91 996 358 1033
More news about: Shantha Biologics
Jun 30, 2026, 09:09 ET Shantha Biologics Announces Cartridge Fill-Finish Collaboration
Dr MRK Raju+91 996 358 1033
More news about: Shantha Biologics
Jun 25, 2026, 15:00 ET Alger Russell Innovation Index Updates for Second Quarter 2026
Merck & Co, Inc.MRKAddition
More news about: Alger
Jun 22, 2026, 16:30 ET Alger Russell Innovation Index Updates for Second Quarter 2026
Merck & Co, Inc.MRKAddition
More news about: Alger
Apr 22, 2026, 08:00 ET Merck and Google Cloud Partner to Accelerate Agentic AI Enterprise Transformation
LAS VEGAS, April 22, 2026 /PRNewswire/ -- Cloud Next '26 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Google Cloud today announced a landmark partnership to enhance Merck's digital backbone as
More news about: Google Cloud
Mar 16, 2026, 16:05 ET Alger Russell Innovation Index Updates for First Quarter 2026
Merck & Co, Inc.MRKDeletion
More news about: Alger
Mar 03, 2026, 09:00 ET Immunotherapy Delivers Across Tumor Types as Oncology Market Eyes $750 Billion
Biotech (NASDAQ: ONCY), Eli Lilly (NYSE: LLY), Gilead Sciences (NASDAQ: GILD), Arcellx (NASDAQ: ACLX), and Merck (NYSE: MRK).
More news about: USA News Group
Mar 02, 2026, 17:31 ET Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight
TransThera Sciences (HKG: 2617), AstraZeneca (LON: AZN), J-Pharma, OHARA Pharmaceutical (TYO: 5218), Compass Therapeutics (NASDAQ: CMPX), Merck (NYSE: MRK), Eisai (TYO: 4523), Seagen (NASDAQ: SGEN), Pfizer (NYSE: PFE), Bold Therapeutics (NASDAQ: BOLD), Senhwa Biosciences, Virogin Biotech, Replimune (NASDAQ:
More news about: DelveInsight Business Research, LLP
Feb 24, 2026, 10:58 ET Oncology Market Set to Nearly Triple: Here Are Five Companies Leading the Charge
oncology sector include Oncolytics Biotech (NASDAQ: ONCY), Exelixis (NASDAQ: EXEL), Eli Lilly (NYSE: LLY), Merck (NYSE: MRK), and Gilead Sciences (NASDAQ: GILD).
More news about: USA News Group
Feb 11, 2026, 17:31 ET EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight
ArriVent BioPharma (NASDAQ: AVBP), Akeso Biopharma (HKG: 9926), Summit Therapeutics (NASDAQ: SMMT), J INTS BIO, Merus (NASDAQ: MRUS), Merck (NYSE: MRK), Kelun-Biotech (HKG: 6990), Genprex (NASDAQ: GNPX), Cullinan Oncology (NASDAQ: CGEM), Taiho Pharma, CSPC Pharmaceutical (HKG: 1093), AbbVie (NYSE: ABBV),
More news about: DelveInsight Business Research, LLP
Jan 27, 2026, 10:50 ET Registration-Ready: How 2026's Clinical Leaders Are Beating Cancer Benchmarks
shift creates an asymmetric investment window for Oncolytics Biotech Inc. (NASDAQ: ONCY), Moderna (NASDAQ: MRNA), Merck (NYSE: MRK), Vir Biotechnology (NASDAQ: VIR), and Coherus Oncology (NASDAQ: CHRS) at the intersection of pivotal execution readiness and combination
More news about: Equity Insider
Dec 09, 2025, 08:52 ET Zydus and Formycon enter into an Exclusive Partnership for the Licensing and Supply of Biosimilar to Keytruda® (Pembrolizumab), in US and Canada
https://www.formycon.com/.1) Keytruda® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc, (NYSE: MRK) Rahway, NJ/USA.Logo:
More news about: Zydus Lifesciences
Oct 29, 2025, 08:30 ET Nanomedicine Innovations Transforming Oncology Drug Delivery and Bioavailability
working to make a difference in cancer treatment, including Iovance Biotherapeutics Inc. (NASDAQ: IOVA), Merck & Co. Inc. (NYSE: MRK), Eli Lilly and Company (NYSE: LLY) and Johnson & Johnson (NYSE: JNJ)
More news about: NetworkNewsWire
Oct 23, 2025, 11:55 ET eschbach's Shiftconnector® Helps Power Merck's Visual Factory to Drive Greater Transparency, Agility, and Supply Chain Resilience
Merck (NYSE: MRK), known as MSD outside the United States and Canada, has selected Shiftconnector to improve how it uses digital tools in manufacturing. By integrating
More news about: eschbach
Oct 21, 2025, 08:23 ET Hoth Therapeutics Reports FDA Orphan Drug Designation and Strong Preclinical Data for HT-KIT in Rare c-KIT-Driven Cancers
dose-escalation/expansion study in advanced systemic mastocytosis and other KIT-driven tumors with translational biomarkers of target engagement (KIT knock-down, tryptase/MRK signaling) and early efficacy readouts (ORR, DCR, PFS signals).
More news about: Hoth Therapeutics, Inc.
Sep 17, 2025, 08:30 ET Advancing Cancer Research Brings New Hope for Patients Worldwide
doing so, it positions itself among the innovators — including Iovance Biotherapeutics Inc. (NASDAQ: IOVA), Merck & Co. Inc. (NYSE: MRK), AstraZeneca PLC (NASDAQ: AZN) and Bristol-Myers Squibb Co. (NYSE: BMY) — that are driving advances in these challenging therapeutic areas.
More news about: NetworkNewsWire